<DOC>
	<DOC>NCT00760838</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and cost-effectiveness of azithromycin as add-on therapy in adult subjects with severe persistent asthma, who remain inadequately controlled despite GINA (2006) step 4 or 5 therapy.</brief_summary>
	<brief_title>AZISAST Study: AZIthromycin in Severe ASThma Study</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>1. patients who have given written informed consent 2. males or females of any race 3. 1875 years of age 4. with the diagnosis of persistent asthma ≥ 1 year duration at screening and a history consistent with GINA step 4 or 5 clinical features 5. receiving high dose ICS plus inhaled LABA for at least 6 months prior to screening 6. patients who have suffered multiple (i.e. at least two) independent documented severe asthma exacerbations within the previous 12 months 7. patients must be neversmokers or exsmokers with a smoking history of ≤ 10 packyears. 1. females who are pregnant or who are breastfeeding 2. patients with severe bronchiectasis 3. patients with active tuberculosis or nontuberculous mycobacterial infections (NTM) 4. patients with significant underlying medical conditions (e.g. infection, hematological disease, malignancy, neurologic, renal, hepatic, coronary heart disease or other cardiovascular disease, endocrinologic or gastrointestinal disease) within the previous 3 months 5. who are unable to perform spirometry or complete a patient diary or complete questionnaires 6. patients with known hypersensitivity to azithromycin or other macrolide antibiotics 7. patients who's heart rate corrected QT interval is prolonged 8. patients who have in the judgement of the investigator a clinically relevant laboratory abnormality 9. patients currently treated with macrolide antibiotics or recent macrolide treatment (in the past twelve weeks) 10. antiIgE treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Inadequately controlled severe asthma</keyword>
</DOC>